# Altay Therapeutics

Source: https://onco.cc/companies/altay-therapeutics/  
OnCo record `altay-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Altay Therapeutics is developing small-molecule drugs for chronic liver disease, including the scarring that leads to liver cancer and liver cancer itself.

## Summary

Altay Therapeutics develops oral small molecules against transcription-factor-driven pathways in liver fibrosis and hepatocellular carcinoma. Its YC profile reports preclinical mouse data showing reduction and partial reversal of fibrosis, and a plan to reach phase 1. The co-founder led early development of pirfenidone, the first approved drug for lung fibrosis. Oncology is one of two stated indications; programmes are preclinical as far as public sources show. Included because liver cancer is an explicit target.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.altaytherapeutics.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/altay-therapeutics
- Official website: https://www.altaytherapeutics.com

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/altay-therapeutics.json